Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in T2DM and Hypercholesterolemia (BANTING)
NCT02739984Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2016
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of evolocumab in hypercholesterolemia, mixed dyslipidemia, sponsored by Amgen. Started May 2016; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT02739984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02739984.